Market Research Life Sciences Market Research Pharmaceuticals Market Research Drug Discovery Market Research

Metabolomics

Best Price Guarantee Length Publisher Published Date SKU
from $5,600 415 Pages Global Industry Analysts January, 2025 GJOB19511392
Best Price Guarantee
Price from $5,600
Length 415 Pages
Publisher Global Industry Analysts
Published Date January, 2025
SKU GJOB19511392

Metabolomics

Global Metabolomics Market to Reach US$7.1 Billion by 2030

The global market for Metabolomics estimated at US$3.3 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2023-2030. Cancer Indication, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Cardiovascular Disorder Indication segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 14.0% CAGR

The Metabolomics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$687.2 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Metabolomics Market – Key Trends & Drivers Summarized
How Is Metabolomics Unlocking New Frontiers in Biological Research?

Metabolomics, the comprehensive study of metabolites in biological systems, is revolutionizing the way researchers understand cellular processes, disease mechanisms, and therapeutic interventions. This cutting-edge field provides insights into the biochemical pathways that govern health and disease by analyzing small molecules within cells, tissues, or biofluids. The rise of metabolomics has enabled scientists to uncover biomarkers for early disease detection, monitor drug efficacy, and personalize treatments for various conditions, including cancer, cardiovascular diseases, and metabolic disorders. Advanced analytical technologies, such as mass spectrometry (MS) and nuclear magnetic resonance (NMR), are central to metabolomics research, allowing for the accurate detection and quantification of complex metabolite profiles. As the demand for precision medicine continues to grow, metabolomics is becoming an indispensable tool in modern biomedical research.

Why Are Pharmaceutical and Healthcare Sectors Investing in Metabolomics?

The pharmaceutical and healthcare sectors are leveraging metabolomics to accelerate drug discovery and enhance patient outcomes. By identifying disease-specific metabolic signatures, researchers can develop targeted therapies and improve the success rates of clinical trials. In drug development, metabolomics facilitates the screening of potential drug candidates, optimizing efficacy while minimizing adverse effects. The technology is also gaining traction in nutritional science, where it is used to evaluate dietary interventions and their impact on metabolic health. Clinical laboratories are increasingly adopting metabolomics for diagnostic purposes, offering more accurate and comprehensive assessments of diseases. Furthermore, the growing emphasis on personalized medicine is driving investments in metabolomics, enabling healthcare providers to tailor treatments to individual patient profiles. This surge in demand is fostering innovation and collaboration between academic institutions, pharmaceutical companies, and diagnostic firms.

How Are Technological Advances Shaping the Metabolomics Landscape?

Technological advancements are at the heart of metabolomics, enhancing the resolution, accuracy, and speed of metabolite analysis. Innovations in high-throughput mass spectrometry and chromatography techniques are enabling the simultaneous detection of thousands of metabolites, providing a holistic view of biological systems. Bioinformatics and machine learning are playing a pivotal role in metabolomics, allowing researchers to analyze large datasets, identify patterns, and derive meaningful insights from complex metabolomic profiles. The integration of multi-omics approaches, combining metabolomics with genomics, proteomics, and transcriptomics, is expanding the scope of research and uncovering new layers of biological complexity. Cloud-based platforms and open-access databases are facilitating global collaboration, making metabolomic data more accessible and enabling cross-disciplinary research. These technological advancements are driving the adoption of metabolomics in diverse fields, from drug development to environmental monitoring, cementing its position as a cornerstone of modern science.

What Factors Are Driving Growth in the Metabolomics Market?

The growth in the metabolomics market is driven by several factors, including the increasing prevalence of chronic diseases, which necessitate advanced diagnostic tools and personalized treatment approaches. The rising demand for precision medicine is a key driver, as metabolomics offers unparalleled insights into individual health profiles and therapeutic responses. Technological innovations, such as advancements in mass spectrometry, NMR, and bioinformatics, are making metabolomic analysis more efficient, accurate, and accessible, attracting investments from pharmaceutical and biotechnology companies. The expansion of multi-omics research is also propelling the adoption of metabolomics, as it enables a comprehensive understanding of biological systems. Furthermore, the growing awareness of the role of nutrition and metabolism in health management is driving the application of metabolomics in personalized nutrition and wellness programs. Collaborative efforts between academia, industry, and regulatory bodies are fostering innovation and standardization in the field, further accelerating market growth. These factors highlight the transformative potential of metabolomics in shaping the future of healthcare and biomedical research.

SCOPE OF STUDY:

The report analyzes the Metabolomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Indication (Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication, Other Indications); Application (Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application, Other Applications); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 63 Featured) -
  • AB Sciex LLC
  • Agilent Technologies, Inc.
  • Biocrates Life Sciences Ag
  • Bruker Corporation
  • Chenomx, Inc.
  • GL Sciences Inc.
  • Human Metabolome Technologies, Inc.
  • LECO Corporation
  • Metabolon, Inc.
  • PerkinElmer, Inc.
  • Shimadzu Scientific Instruments
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Metabolomics: Transforming Healthcare with Insight into Metabolic Pathways and Biomarkers
Global Economic Update
EXHIBIT 1: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
EXHIBIT 2: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
EXHIBIT 3: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
Competition
EXHIBIT 4: Metabolomics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Introduction to Metabolomics
Analytical Techniques in Metabolomics
The Metabolomics Workflow: Key Stages
Applications of Metabolomics
Recent Market Activity
Influencer/Product/Technology Insights
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Development of Novel Biomarkers for Disease Detection Drives Widespread Adoption of Metabolomics in Clinical Diagnostics
Metabolomics in Drug Research and Development: A Pathway to Precision Medicine
Growing Focus on Personalized Healthcare and Patient-Centric Solutions Expands Addressable Market for Targeted Metabolomics Applications
EXHIBIT 5: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
Growing Multidisciplinary Role of Metabolomics in Toxicology Testing
Rising Demand for Nutrigenomics Throws the Spotlight on Nutritional Metabolomics Applications for Customized Diet Planning
Growing Investment in Cancer Research Propels Growth in Oncology-Focused Metabolomics Studies and Applications
EXHIBIT 6: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2022 and 2050
EXHIBIT 7: Global Cancer Incidence by Region: 2022
Integration of AI, Machine Learning, and Big Data Analytics Expands the Potential of Metabolomics Data for Predictive Modeling and Insights
Advancements in Mass Spectrometry and Analytical Tools Strengthen the Business Case for Large-Scale Metabolomics Research
Global Shift Toward Precision Medicine Accelerates Adoption Of Metabolomics
Role of Metabolomics in Inborn Errors of Metabolism (IEMs): Current Advancements and Future Directions
Harnessing Metabolomics for Crop Improvement and Sustainable Agriculture
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Metabolomics Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 4: World 12-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 7: World 12-Year Perspective for Cancer Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Cardiovascular Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 10: World 12-Year Perspective for Cardiovascular Disorder Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Neurological Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Neurological Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 13: World 12-Year Perspective for Neurological Disorder Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Inborn Errors of Metabolism Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Inborn Errors of Metabolism Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 16: World 12-Year Perspective for Inborn Errors of Metabolism Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 19: World 12-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Biomarker Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Biomarker Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 22: World 12-Year Perspective for Biomarker Discovery Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 25: World 12-Year Perspective for Drug Discovery Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Toxicology Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Toxicology Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 28: World 12-Year Perspective for Toxicology Testing Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Nutrigenomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Nutrigenomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 31: World 12-Year Perspective for Nutrigenomics Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 34: World 12-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 37: World 12-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 40: World 12-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 42: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 43: World 12-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 45: World Historic Review for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 46: World 12-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
TABLE 47: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 48: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 49: World 12-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Market Analytics
TABLE 50: USA Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: USA Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 52: USA 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: USA Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 55: USA 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 56: USA Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: USA Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 58: USA 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
CANADA
TABLE 59: Canada Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 61: Canada 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 64: Canada 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 65: Canada Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Canada Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 67: Canada 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
JAPAN
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Market Analytics
TABLE 68: Japan Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 70: Japan 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 73: Japan 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 74: Japan Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 76: Japan 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
CHINA
TABLE 77: China Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: China Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 79: China 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: China Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 82: China 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 83: China Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: China Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 85: China 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
EUROPE
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Market Analytics
TABLE 86: Europe Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 88: Europe 12-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2024 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 91: Europe 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 94: Europe 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 95: Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 97: Europe 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
FRANCE
TABLE 98: France Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: France Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 100: France 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 101: France Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: France Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 103: France 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 104: France Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: France Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 106: France 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
GERMANY
TABLE 107: Germany Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 109: Germany 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 110: Germany Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Germany Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 112: Germany 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 113: Germany Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: Germany Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 115: Germany 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
ITALY
TABLE 116: Italy Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 118: Italy 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 119: Italy Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: Italy Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 121: Italy 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 122: Italy Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: Italy Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 124: Italy 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
UNITED KINGDOM
TABLE 125: UK Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: UK Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 127: UK 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 128: UK Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: UK Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 130: UK 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 131: UK Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: UK Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 133: UK 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
REST OF EUROPE
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 136: Rest of Europe 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 139: Rest of Europe 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 142: Rest of Europe 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
ASIA-PACIFIC
Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Market Analytics
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 145: Asia-Pacific 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 148: Asia-Pacific 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 151: Asia-Pacific 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
REST OF WORLD
TABLE 152: Rest of World Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of World Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 154: Rest of World 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
TABLE 155: Rest of World Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 156: Rest of World Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 157: Rest of World 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
TABLE 158: Rest of World Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 159: Rest of World Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
TABLE 160: Rest of World 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
IV. COMPETITION

$5,600
$16,800

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings